A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC
DOMA Perpetual Capital Management, a significant shareholder in Pacira BioSciences, has sent a letter to Pacira shareholders criticizing the current management and board for persistent underperformance and mismanagement of EXPAREL patent litigation. DOMA highlights Pacira's poor total shareholder return over several years and claims the board's handling of patent risk amounts to gross negligence. They propose a well-executed, board-supervised process to explore strategic alternatives, including a potential sale, as the best path to protect and generate shareholder value, urging shareholders to vote for their nominees.
Doma Perpetual urges Pacira BioSciences shareholders to judge sale price adequacy
Doma Perpetual Capital, an activist investor, is urging shareholders of Pacira BioSciences (PCRX) to critically evaluate the adequacy of any potential sale price for the company. This comes amidst ongoing shareholder activism from Doma Perpetual, which has previously called for the removal of Pacira's CEO and a strategic sale. The company, which specializes in non-opioid pain treatments such, is currently trading at $23.48 with an average analyst target price of $29.29.
DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences
DOMA Perpetual Capital Management, which beneficially owns about 7.5% of Pacira BioSciences, has released a joint letter from its two independent director nominees, Christopher Dennis and Oliver Benton Curtis III, to Pacira shareholders. The nominees aim to bring fresh perspectives and rigorous questioning to the Company's board, challenging the current board's claims about Pacira's performance and strategy. They advocate for a comprehensive, independent review of strategic alternatives, strengthened oversight, and clear communication with shareholders to maximize value.
Pacira BioSciences Files Investor Presentation Highlighting
Pacira BioSciences has released an investor presentation emphasizing the successful execution of its long-term strategy, the 5x30 plan, which has led to record financial performance in 2025 and continued growth in Q1 2026. The company also highlights its disciplined capital allocation, successful patent litigation settlement, and a board with strong biopharmaceutical expertise, urging shareholders to vote for its highly qualified nominees against those of DOMA Perpetual Capital Management LLC.
Pacira Q1 earnings miss estimates on higher costs, revenues rise y/y
Pacira BioSciences reported a mixed Q1 earnings, with revenues increasing year-over-year but earnings per share missing analyst estimates. The company's miss on EPS was attributed to higher costs during the quarter.
Pacira BioSciences: Exparel Still Supports My Original Bull Case (NASDAQ:PCRX)
Pacira BioSciences (PCRX) is a non-opioid pain company primarily built around Exparel, with Zilretta and Iovera offering some diversification. The author believes upcoming 2026 pipeline readouts will be crucial catalysts, despite concerns about the company's overdependence on Exparel and other biotech risks. The recent pullback in PCRX's stock price presents a discount, leading to a reiteration of a "Buy" rating.
(PCRX) Volatility Zones as Tactical Triggers
This article analyzes Pacira Biosciences Inc. (NASDAQ: PCRX) using AI models to identify volatility zones as tactical triggers. Key findings indicate weak near and mid-term sentiment but a neutral long-term outlook, with an exceptional 41.6:1 risk-reward setup. The analysis provides specific trading strategies (Position, Momentum Breakout, Risk Hedging) and multi-timeframe signal analysis to optimize trading decisions.
UBS Group AG Has $14.46 Million Position in Pacira BioSciences, Inc. $PCRX
UBS Group AG reduced its stake in Pacira BioSciences (NASDAQ:PCRX) by 34.7% in the fourth quarter, selling 296,210 shares to hold 558,651 shares valued at $14.46 million. Despite this, other institutional investors increased their positions in the company, which reported mixed quarterly results with an EPS miss but a revenue beat. Analyst sentiment for Pacira BioSciences is currently mixed, with a consensus "Hold" rating and an average price target of $29.40.
Pacira BioSciences stock (US6951271005): Activist investor DOMA nominates three board directors
Activist investor DOMA Perpetual Capital Management, holding a 7.5% stake in Pacira BioSciences, has nominated three independent directors to the company's board. This move comes amidst concerns over Pacira's modest 4% revenue growth in 2025 contrasted with sharp increases in R&D (44%) and SG&A (25%) expenses, raising questions about the company's capital allocation and operational efficiency. The proxy contest brings governance and strategic execution into focus for the specialty pharmaceutical company.
[DFAN14A] Pacira BioSciences, Inc. SEC Filing
DOMA Perpetual Capital Management, a significant shareholder of Pacira BioSciences (PCRX), has filed a definitive proxy statement urging shareholders to vote for their three independent board candidates. DOMA Perpetual contends that Pacira's current board and management are exhibiting gross negligence by misleading investors about business risks, particularly concerning their reliance on the EXPAREL product and costly patent litigation. The firm highlights Pacira's significant underperformance, declining stock price, increased executive compensation despite negative net income, and a lack of risk management expertise on the board, advocating for a strategic sale of the company and the removal of the current CEO to maximize shareholder value.
DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board Candidates
DOMA Perpetual, a significant shareholder in Pacira BioSciences, has sent a letter urging fellow shareholders to vote for its three independent board nominees. DOMA argues that Pacira's current board and management are
Vanguard Group Inc. Sells 384,612 Shares of Pacira BioSciences, Inc. $PCRX
Vanguard Group Inc. reduced its stake in Pacira BioSciences, Inc. by 7.4% in the fourth quarter, selling 384,612 shares and retaining 4.81 million shares valued at approximately $124.6 million. Insider selling also continued, with CFO Shawn Cross and Jonathan Slonin selling shares. Pacira BioSciences recently reported mixed quarterly results, with EPS missing estimates but revenue exceeding expectations and increasing 5% year-over-year.
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
Pacira BioSciences has sent a letter to its stockholders ahead of its 2026 Annual Meeting, emphasizing the superior qualifications of its board nominees—Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans—and urging stockholders to vote "FOR" them on the BLUE proxy card. The company asserts that its nominees possess the necessary experience and skills to guide Pacira's long-term strategy and drive sustainable growth, contrasting this with the alleged underqualification and lack of relevant industry experience of DOMA Perpetual Capital Management LLC's candidates. Pacira also highlights its focused 5x30 plan as critical for value creation, while criticizing DOMA for a lack of a clear plan and a fundamental misunderstanding of the biotechnology industry and Pacira's business.
Biotech Pacira warns rival board picks risk 'value destruction' in letter
Pacira BioSciences is urging stockholders to support its three board nominees for the upcoming Annual Meeting on June 9, 2026, arguing that their experience is crucial for the company's 5x30 growth strategy. The company asserts that the alternative slate of nominees proposed by DOMA Perpetual Capital Management LLC lacks relevant biopharmaceutical and public board experience, posing a risk of "value destruction." Pacira emphasizes its nominees' expertise in government, drug development, M&A, and commercialization, contrasting it with what it describes as DOMA's fundamental misunderstanding of the biotech industry.
Activist DOMA (PCRX) Seeks CEO Removal, Board Seats; Pushes Sale Vote
Activist investor DOMA Perpetual has filed a preliminary proxy statement to elect three new directors to Pacira BioSciences' board and to remove the current CEO ahead of the June 9, 2026, annual meeting. DOMA, which beneficially owns a significant stake in Pacira, argues that the current board has mismanaged the company, particularly regarding its flagship product EXPAREL and capital allocation. DOMA proposes an action plan including the CEO's removal, appointment of an interim CEO, creation of a subcommittee to oversee a sale process, and a shareholder vote on any proposed sale price.
Earnings call transcript: Pacira BioSciences Q1 2026 earnings exceed forecasts
Pacira BioSciences reported strong Q1 2026 results, surpassing EPS and revenue forecasts with $0.60 EPS and $177 million in revenue, respectively. Despite a post-earnings stock dip, the company is confident in its 5x30 strategy for sustainable growth, driven by product sales, pipeline advancements, and strategic partnerships. Key challenges include margin compression and increased R&D expenses as it advances its clinical pipeline and maintains its full-year guidance.
Earnings call transcript: Pacira BioSciences Q1 2026 earnings exceed forecasts By Investing.com
Pacira BioSciences reported strong financial results for Q1 2026, with EPS of $0.60 and revenue of $177 million, both exceeding analyst forecasts. Despite initial stock decline post-earnings, the company demonstrated recovery in pre-market trading, driven by strategic initiatives and strong product sales for EXPAREL, ZILRETTA, and iovera. The company reiterated its full-year guidance and remains confident in its "5x30" strategy for sustainable growth.
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences announced inducement awards granted to ten new employees on May 4, 2026, under its Amended and Restated 2014 Inducement Plan. These awards, consisting of stock options and restricted stock units for an aggregate of 36,800 and 27,700 shares respectively, were approved by the People & Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4) as a material inducement for their employment. The grants aim to attract and retain talent for the company.
Pacira BioSciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences announced that it is reporting inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). The article also lists recent news about the company, including financial results, analyst ratings, and developments regarding its key products EXPAREL and ZILRETTA. Access to the full article on MarketScreener is reserved for members.
10 new Pacira hires get stock options and restricted units
Pacira BioSciences granted inducement equity awards to ten new employees on May 4, 2026, under its Amended and Restated 2014 Inducement Plan. These awards include 36,800 stock options and 27,700 restricted stock units, approved by the People & Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are intended to attract and retain talent, with options vesting over four years at an exercise price of $24.69 and RSUs vesting annually over four years starting May 4, 2027.
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences announced inducement grants to ten new employees on May 4, 2026, under its Amended and Restated 2014 Inducement Plan. These awards, consisting of stock options and restricted stock units, were approved by the Board's People & Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4) and are a material inducement for their employment. The grants are subject to vesting schedules and continued employment with Pacira.
Pacira BioSciences Reports Strong Q1 2026 Results and Highlights Success of 5x30 Strategy, Urges Stockholders to Vote "FOR" Board Nominees
Pacira BioSciences announced strong Q1 2026 results, with a 5% revenue increase and positive performance across its key products, attributing success to its 5x30 strategy. The company is engaged in a proxy fight with DOMA Perpetual Capital Management and is urging stockholders to vote "FOR" its board nominees to protect its strategic progress and long-term vision. Pacira highlights its robust clinical pipeline, expanded commercial reach through partnerships, and disciplined capital deployment, while stressing that DOMA's "strategy" lacks a clear plan for stockholder value.
Pacira BioSciences Reports Strong Q1 2026 Results and Highlights Success of 5x30 Strategy, Urges Stockholders to Vote "FOR" Board Nominees
Pacira BioSciences announced strong Q1 2026 results, with a 5% revenue increase and positive performance across its key products, attributing success to its 5x30 strategy. The company is actively engaged in a proxy fight with DOMA Perpetual Capital Management and is urging stockholders to vote "FOR" its board nominees to protect strategic progress and prevent potential disruptions. Pacira highlighted its strong financial health, pipeline advancements, and expanded market reach through partnerships.
Pacira BioSciences Mails Letter to Stockholders
Pacira BioSciences has mailed a letter to its stockholders ahead of its 2026 Annual Meeting. The letter highlights the success of the company's 5x30 strategy, strong first-quarter 2026 results, and reiterates the board's recommendation to vote for its nominees against DOMA Perpetual Capital Management LLC's candidates. Pacira emphasizes its progress in patient numbers, product revenue growth, profitability, pipeline development, and strategic partnerships, while criticizing DOMA's "strategy" as lacking a clear plan and risking the company's long-term value.
How Pacira’s Q1 2026 Results, EXPAREL Data and Proxy Battle May Impact Pacira BioSciences (PCRX) Investors
Pacira BioSciences (PCRX) recently announced Q1 2026 results with modest revenue growth but softened earnings. The company also highlighted new real-world Medicare data for its drug EXPAREL, showing reduced opioid use and medical costs, which could strengthen its non-opioid pain management narrative. This comes as Pacira faces an activist proxy battle, potentially adding governance complexities for investors.
How Pacira’s Q1 2026 Results, EXPAREL Data and Proxy Battle May Impact Pacira BioSciences (PCRX) Investors
Pacira BioSciences (PCRX) recently posted Q1 2026 results with modest revenue growth and softer earnings. The company also highlighted real-world data for EXPAREL showing reduced opioid use and medical costs. This comes amidst an activist proxy battle with DOMA Perpetual Capital Management, adding governance complexity ahead of the June 2026 shareholder meeting.
Pacira BioSciences (PCRX) Return To Profitability Tests Bullish Growth Narratives
Pacira BioSciences (PCRX) began 2026 with a return to profitability, reporting Q1 revenue of US$177.4 million and basic EPS of US$0.07, and maintaining positive net income for the trailing twelve months. While bulls highlight this return, the company has a five-year earnings decline of 55.6% and significant quarterly profit swings, with bears pointing to one-off losses and past declines that question the quality of current profitability. The article suggests that investors should treat the recent profitability as a starting point and closely examine the mixed picture of profits, one-off items, and valuation signals.
Universal Beteiligungs und Servicegesellschaft mbH Boosts Stock Position in Pacira BioSciences, Inc. $PCRX
Universal Beteiligungs und Servicegesellschaft mbH significantly increased its stake in Pacira BioSciences (PCRX) by 360.1% in Q4, now owning 69,097 shares valued at $1.79 million. Pacira BioSciences recently reported mixed Q1 results with revenue growth and strong pipeline progress but issued cautious FY2026 guidance, leading to a negative market reaction. Analyst ratings are mixed, with Needham raising its price target to $32 while the consensus remains a "Hold" at $29.40, and insiders have sold shares.
Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
Pacira BioSciences (PCRX) reported first-quarter 2026 adjusted earnings of 60 cents per share, missing estimates, despite a 5% year-over-year revenue increase to $177.4 million, driven by strong Exparel demand and growth in Zilretta and iovera sales. The company's profitability was impacted by a 10% rise in research and development and selling, general, and administrative expenses. Pacira reaffirmed its full-year 2026 revenue guidance and detailed upcoming catalyst-rich periods, including data from Phase III and Phase II studies for Zilretta, iovera, and PCRX-201.
Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
Pacira BioSciences (PCRX) reported first-quarter 2026 adjusted earnings of 60 cents per share, missing the Zacks Consensus Estimate of 61 cents, despite a 5% year-over-year revenue increase to $177.4 million, which beat expectations. Higher operating expenses due to increased R&D and SG&A weighed on profitability. The company reaffirmed its full-year 2026 financial guidance and is anticipating key data readouts from its late-stage pipeline programs, including Zilretta and iovera studies, and continued development of its gene therapy candidate, PCRX-201.
Royal Bank Of Canada Issues Positive Forecast for Pacira BioSciences (NASDAQ:PCRX) Stock Price
Royal Bank of Canada has increased its price target for Pacira BioSciences (NASDAQ:PCRX) to $24, while maintaining a "sector perform" rating. This adjustment suggests a slight downside for the stock, though other analysts have a higher average target of $29.40. Despite underlying commercial momentum, the company's FY-2026 revenue guidance fell slightly below consensus, which has put pressure on the stock.
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up Following Analyst Upgrade
Pacira BioSciences (NASDAQ:PCRX) gapped up after Needham & Company LLC raised its price target from $30.00 to $32.00, maintaining a buy rating. Despite mixed analyst coverage with a consensus "Hold" and an average price target of $30.75, the company reported a strong Q1 beat and progress in its clinical trials. Insider selling has been noted, with CFO Shawn Cross selling a significant number of shares.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2026 Earnings Call Transcript
Pacira BioSciences, Inc. reported strong Q1 2026 results, surpassing earnings expectations with EPS of $0.6. The company highlighted the success of its "Five by 30" strategy, driving growth across its flagship product EXPAREL and other key products like ZILRETTA and ioverao, while also advancing a promising clinical-stage pipeline. Pacira is confident in delivering sustainable growth and value creation well into 2030, supported by strategic partnerships and a disciplined approach to capital deployment, including share repurchases.
[ARS] Pacira BioSciences, Inc. SEC Filing
This article announces an ARS SEC filing by Pacira BioSciences, Inc. (PCRX), classifying its impact as low and sentiment as neutral. The filing, dated April 28, 2026, concerns an Annual Report to Security Holders. The article also provides a company overview, recent news, and other SEC filings for Pacira BioSciences, Inc.
Press Release: Pacira BioSciences Reports First Quarter 2026 Financial Results
Pacira BioSciences has reported its financial results for the first quarter of 2026. The company is expected to provide detailed information regarding its financial performance, key business updates, and future outlook in the full report. This announcement will be of interest to investors and stakeholders following the pharmaceutical sector.
[8-K] Pacira BioSciences, Inc. Reports Material Event
Pacira BioSciences (NASDAQ: PCRX) reported Q1 2026 revenue of $177.4 million, a 5% increase year-over-year, driven by strong growth in its non-opioid pain portfolio, including EXPAREL, ZILRETTA, and iovera°. Despite a decline in GAAP and non-GAAP net income due to increased R&D and SG&A spending, the company reaffirmed its full-year 2026 financial guidance and highlighted key clinical advancements. These include completing enrollment for a Phase 3 ZILRETTA study in shoulder osteoarthritis and progress with its gene therapy candidate PCRX-201.
Pacira BioSciences Q1 2026 Earnings Call Transcript
Pacira BioSciences reported strong Q1 2026 results, driven by their "5 by 30" strategy, which focuses on patients served, product, revenue, profitability, pipeline, and partnerships. Flagship product Exparel saw renewed growth with a 7% volume increase, supported by expanded reimbursement and intellectual property protection. Zilretta and Iovera also experienced sales growth of 15% and 21% respectively, due to dedicated sales forces and strategic collaborations, with key clinical milestones anticipated for PCRX201 and PCRX2002 later this year.
Earnings Flash (PCRX) Pacira BioSciences, Inc. Reports Q1 Revenue $177.4M, vs. FactSet Est of $171.8M
Pacira BioSciences, Inc. (PCRX) announced Q1 revenue of $177.4 million, surpassing FactSet's estimate of $171.8 million. The report also highlights recent company news, including Q1 adjusted EPS of $0.60 per share against an estimated $0.55, and real-world data demonstrating the benefits of EXPAREL in reducing opioid use and healthcare costs. The company's main products are EXPAREL, ZILRETTA, and Iovera, focusing on non-opioid pain management.
Pacira BioSciences Reports First Quarter 2026 Financial Results
Pacira BioSciences reported strong first-quarter 2026 financial results, with total revenue increasing 5% to $177 million, driven by growth across its commercial portfolio including EXPAREL, ZILRETTA, and iovera°. The company also highlighted advancements in its pipeline, including the completion of enrollment for a Phase 3 ZILRETTA study in shoulder osteoarthritis and upcoming data readouts for PCRX-201 and iovera° in spasticity. Pacira reiterated its full-year 2026 financial guidance, anticipating continued durable revenue growth and clinical innovation.
Pacira BioSciences Reports First Quarter 2026 Financial Results
Pacira BioSciences reported strong first-quarter 2026 financial results with total revenue of $177 million, a 5% increase over Q1 2025, driven by growth in its commercial portfolio including EXPAREL, ZILRETTA, and iovera°. The company also announced the completion of patient enrollment for a Phase 3 study of ZILRETTA in shoulder osteoarthritis, with topline results expected by year-end, and reiterated its full-year 2026 financial guidance. These achievements highlight the continuous success of its 5x30 strategy focused on durable revenue growth and clinical innovation.
Pacira BioSciences Reports First Quarter 2026 Financial Results
Pacira BioSciences reported strong financial results for the first quarter of 2026, with total revenue reaching $177 million, a 5% increase year-over-year, driven by growth across its commercial portfolio including EXPAREL, ZILRETTA, and iovera°. The company also announced the completion of patient enrollment for a Phase 3 study of ZILRETTA in shoulder osteoarthritis, with topline results expected by year-end, and reaffirmed its full-year 2026 financial guidance.
Pacira BioSciences Inc. (PCRX) Stock Rises on Q4 2025 Earnings
Pacira BioSciences Inc. (PCRX) reported fourth-quarter fiscal 2025 results with revenue of $196.9 million, exceeding estimates, despite diluted earnings per share falling short. The company saw an increase in operating cash flow and a decrease in total liabilities. Insider trading activity indicates several sales by executives, while hedge funds show mixed positions with significant additions and removals of shares. Analyst ratings are predominantly "Buy" with a median price target of $29.0.
Pacira BioSciences Inc. (PCRX) Stock Rises on Q4 2025 Earnings
Pacira BioSciences Inc. (PCRX) announced its Q4 2025 earnings, reporting a revenue of $196.9 million, exceeding estimates, while diluted EPS was $0.04, below expectations. The company saw an increase in operating cash flow and a decrease in total liabilities, leading to a 1.43% rise in its stock price post-market. Insider trading activity shows multiple sales but no purchases, and institutional investors displayed mixed activity with some adding and others decreasing their positions.
Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders
Pacira BioSciences has filed definitive proxy materials and mailed a letter to shareholders for its 2026 Annual Meeting on June 9, 2026, urging them to vote for its highly qualified nominees Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans on the BLUE proxy card. The company asserts it is well-positioned for growth, successfully executing its 5x30 strategy, and has a strong patent portfolio, while strongly opposing nominees from DOMA Perpetual Capital Management, which it describes as underqualified and disruptive. Pacira highlights its operational progress, financial performance, pipeline advancements, and strong board governance to defend its recommended slate of directors.
Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025
Pacira BioSciences, Inc. announced it will release its first-quarter 2025 financial results on Thursday, May 8, 2025. The company will also host a conference call and webcast to discuss the results and provide a business update.
Medicare hip patients used fewer opioids in EXPAREL study
A real-world study presented by Pacira BioSciences showed that Medicare patients undergoing total hip arthroplasty who received EXPAREL (bupivacaine liposome) experienced significantly reduced opioid consumption, fewer inpatient admissions and outpatient visits, and lower total medical costs over a 12-month period compared to those receiving non-liposome bupivacaine. This data reinforces EXPAREL's role in reducing opioid exposure and healthcare resource utilization, particularly in the vulnerable Medicare population.
Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty
A real-world study presented at the ASRA Annual Meeting revealed that EXPAREL® (bupivacaine liposome injectable suspension) significantly reduced opioid use, healthcare resource utilization, and total medical costs for Medicare patients undergoing total hip arthroplasty. Patients administered EXPAREL experienced lower inpatient admissions, emergency department visits, outpatient admissions, and fewer opioid-related adverse events over a 12-month period compared to those receiving non-liposome bupivacaine. These findings underscore EXPAREL's value in reducing opioid exposure and healthcare burdens, particularly in the vulnerable Medicare population.
Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty
A real-world study presented at the ASRA Annual Meeting analyzed the clinical and economic impact of EXPAREL® (bupivacaine liposome injectable suspension) in Medicare patients undergoing outpatient total hip arthroplasty. The study found that EXPAREL was associated with significant reductions in opioid use, healthcare resource utilization (inpatient admissions, ED visits, outpatient admissions), and total medical costs over a 12-month period compared to standard-of-care options. These findings highlight EXPAREL's role in reducing opioid exposure and offering economic value in this patient population.
Pacira drops after adjusting 2025 revenue below consensus
Pacira BioSciences (PCRX) stock dropped over 11% following its Q1 2024 earnings call where the company adjusted its 2025 revenue guidance to a range of $675-$735 million, falling below the average analyst estimate of $754 million. This downward revision was primarily attributed to slower than expected adoption of its newly approved nerve block, EXPAREL, in certain surgical settings. Despite reaffirming its 2024 revenue guidance, the weaker outlook for 2025 disappointed investors.
PCRX Price Today: Pacira BioSciences, Inc. Stock Price, Quote & Chart | MEXC
This article provides current stock information for Pacira BioSciences, Inc. (PCRX), including its live price, market data like market cap and volume, and recent price changes. It also details how to buy PCRX shares on MEXC, an overview of the company's non-opioid pain management solutions, and answers frequently asked questions about its financial performance and valuation.
